Following this approach, numerous clinical trials aim to induce anti-tumor effects with a specific HER2–directed T-cell response by using peptide-based vaccines or viral vectors and self-replicating RNA-based cancer vaccines administered alone or in conjunction with immune checkpoint inhibitor anti-PD1 mABs [19,175,176]. The gene discussed is ERBB2; the disease is cancer.